Business Context and Reporting Period
Company: 20/20 Biolabs, Inc. (Nasdaq: AIDX)
Filing Type: Form 8-K (Current Report)
Report Date: April 28, 2026
Event Date: April 23, 2026
Context: The Company is an emerging growth company reporting the entry into a material definitive agreement regarding the amendment of existing warrant terms with Streeterville Capital, LLC.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The financial data provided relates strictly to capital structure and financing terms:
- Secured Convertible Notes: Aggregate principal amount up to $570,000 issued in two tranches ($295,000 and $275,000).
- Series E Preferred Stock: Commitment amount up to $40,000,000; $5,000,000 issued to date (5,000 shares at $1,000/share).
- Warrant Exercise Price (Original): Varied between $8.00 and $11.42 per share depending on the issuance date and Nasdaq Price.
- Warrant Exercise Price (Amended): Reduced to $2.25 per share.
Material Changes
The primary material change reported is the execution of a Global Amendment on April 23, 2026, with Streeterville Capital, LLC. Key changes include:
- Exercise Price Reduction: The exercise price for all outstanding warrants (Warrant 1, Warrant 2, and Warrant 3) was reduced from their original terms ($8.00 or $11.42) to $2.25 per share.
- Termination Right: The Company retains the right to terminate this Amendment within 90 days of execution upon providing at least two trading days' written notice.
- Share Count Impact: The amendment affects warrants covering approximately 3,627,627 shares of common stock (62,500 + 62,500 + 3,502,627).
Outlook, Risks, and Management Commentary
Management Commentary: The filing summarizes the terms of the amendment but does not include forward-looking guidance, earnings outlook, or strategic commentary beyond the transaction details.
Risks and Contingencies:
- Dilution Risk: The significant reduction in the warrant exercise price to $2.25 increases the potential for future dilution to existing shareholders if the warrants are exercised.
- Termination Uncertainty: The 90-day termination window creates uncertainty regarding the finality of the $2.25 exercise price.
- Valuation Discrepancy: The new exercise price ($2.25) is substantially lower than the Nasdaq Price established at the time of the direct listing ($11.42).
Investor Verification Checklist
- Verify the total number of shares underlying the amended warrants and the potential dilution impact at the $2.25 exercise price.
- Confirm the Company's current cash position and liquidity needs necessitating this price reduction.
- Monitor the 90-day termination window to determine if the Company exercises its right to revert the terms.
- Review the full text of the Global Amendment (Exhibit 4.4) for any additional covenants or conditions not summarized in the 8-K.
- Check subsequent filings for any updates on the status of the remaining $35,000,000 commitment under the Series E preferred stock agreement.